IONS Overview
Upcoming Projects (IONS)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (IONS)
-
Discussing Arrowhead's plozasiran for managing persistent chylomicronemia and pancreatitis risk with FCS after receiving FDA breakthrough therapy designation
Tickers: ARWR, IONS
Executed On: Sep 12, 2024 at 03:00 PM EDT -
Examining Ionis' Phase 1/2a results (six-month data) on ION582 in treating Angelman syndrome
Ticker: IONS
Executed On: Jul 29, 2024 at 03:00 PM EDT -
Discussing the results from the OASIS-HAE and OASISplus studies of donidalorsen in patients with hereditary angioedema
Ticker: IONS
Executed On: Jun 21, 2024 at 11:30 AM EDT -
Discussing Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
Tickers: ARWR, IONS
Executed On: Jun 13, 2024 at 03:00 PM EDT -
Discussing the potential of WAINUA (eplontersen) as an FDA approved treatment for patients with hereditary transthyretin-mediated amyloid polyneuropathy.
Tickers: AZN, IONS
Executed On: Mar 14, 2024 at 05:45 PM EDT -
Discussing Familial Chylomicronemia Syndrome (FCS), volanesorsen, and the recent Phase 3 topline results of olezarsen.
Ticker: IONS
Executed On: Oct 06, 2023 at 01:00 PM EDT -
Discussing the potential of AstraZeneca and Ionis’ eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy with a neurologist.
Tickers: AZN, IONS
Executed On: May 31, 2023 at 04:00 PM EDT -
Discussing Biogen's Tofersen (BIIB067), an antisense drug being evaluated as a treatment for SOD1-ALS
Tickers: BIIB, IONS
Executed On: Feb 28, 2023 at 02:00 PM EST -
Discussing new treatments for ALS with members of The ALS Association
Tickers: AMLX, IONS
Executed On: Mar 18, 2022 at 03:00 PM EDT
Expired Projects (IONS)
-
What Does the Future Hold for Ionis Pharma’s Obesity Drug FGFR4Rx with Phase 2a Nearing Completion?
Ticker: IONS
Execute By: Nov 22, 2016
Upcoming & Overdue Catalysts (IONS)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (IONS)
-
Silence Therapeutics (SLN) Sues Alnylam (ALNY) on dispute over commercialization of ONPATTRO (patisiran) in the EU
Tickers: ALNY, IONS, SLN.L, AKCA
Occurred on: Oct 11, 2018 -
PDUFA date of October 6, 2018 announced for Ionis'(IONS) Inotersen in hereditary TTR amyloidosis
Ticker: IONS
Occurred on: Oct 05, 2018 -
Ionis Pharmaceuticals (IONS) to submit to EMA for Inotersen, which treats TTR amyloidosis, by end of 2017
Ticker: IONS
Occurred on: Jun 01, 2018 -
FDA Ad-Comm Votes in Favor of WAYLIVRA(volanesorsen) for Treatment of Familial Chylomicronemia Syndrome
Tickers: AKCA, IONS
Occurred on: May 10, 2018 -
Ionis Pharmaceuticals (IONS) to submit regulatory application for Inotersen, which treats TTR amyloidosis, to US FDA by end of 2017
Ticker: IONS
Occurred on: Nov 06, 2017 -
Ionis Pharmaceuticals (IONS) to preparing to file Volanesorsen, which treats patients with FCS, to US FDA in Q3 of 2017
Ticker: IONS
Occurred on: Aug 31, 2017 -
Ionis Pharma (IONS) to report on Phase 3 study of IONIS-SMN Rx in Infants with Spinal Muscular Atrophy in the summer of 2017
Ticker: IONS
Occurred on: Apr 24, 2017 -
Phase 3 Nusinersen CHERISH trial data due in 2017
Ticker: IONS
Occurred on: Apr 24, 2017 -
UnitedHealth (UNH) to Begin Coverage on April 1st for Ionis (IONS) and Biogen's (BIIB) Spinraza in Treatment of Spinal Muscular Atrophy (SMA)
Tickers: IONS, BIIB, UNH
Occurred on: Apr 01, 2017 -
Ionis Pharma (IONS) to complete Phase 2a study of ISIS 463588 (ISIS-FGFR4RX) in Obese Patients in 2016
Ticker: IONS
Occurred on: Feb 07, 2017 -
Phase 3 data from CHERISH and ENDEAR (study evaluating nusinersen in infants with SMA) expected in 2017
Ticker: IONS
Occurred on: Jan 26, 2017 -
ENDEAR trial in children with spinal muscular atrophy SMA Data are due 2017
Ticker: IONS
Occurred on: Jan 13, 2017 -
Ionis Pharma (IONS) to complete Phase 2 study of ISIS-GCGRRx in Patients With Type 2 Diabetes before 2017
Ticker: IONS
Occurred on: Jan 04, 2017 -
Akcea and Ionis (IONS) Announce Positive Results from COMPASS Phase 3 Study of Volanesorsen
Tickers: IONS, Akcea Therapeutics
Occurred on: Dec 19, 2016 -
Ionis Pharmaceuticals (IONS) Reports Clinical Data from IONIS-ANGPTL3-L Rx
Ticker: IONS
Occurred on: Nov 15, 2016 -
Biogen (BIIB) and Ionis (IONS) Announce Phase 3 CHERISH Interim Results Evaluating SPINRAZA in Later-Onset Spinal Muscular Atrophy (SMA)
Tickers: IONS, BIIB
Occurred on: Nov 07, 2016 -
Ionis Pharma (IONS) to complete Phase 1/2a study of ISIS-DMPKRx in Adults with Myotonic Dystrophy Type 1 by end of 2016
Ticker: IONS
Occurred on: Nov 02, 2016 -
Ionis Pharma (IONS) to finish Phase 2 study of IONIS-FXIrx administered to Patients with End-Stage Renal Disease on Hemodialysis in Fall 2016
Tickers: IONS, BAYRY
Occurred on: Nov 01, 2016 -
Biogen (BIIB) Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for Spinal Muscular Atrophy
Tickers: BIIB, IONS
Occurred on: Sep 26, 2016 -
Akcea Announces Publication in The Lancet of Clinical Results with Lp(a)-Lowering Drugs Designed to Treat Cardiovascular Disease
Ticker: IONS
Occurred on: Sep 22, 2016 -
Akcea Therapeutics Receives Orphan Designation in Europe for Volanesorsen for the Treatment of Familial Partial Lipodystrophy (FPL)
Ticker: IONS
Occurred on: Jul 28, 2016 -
Ionis Pharmaceuticals Reports Positive Clinical Data on IONIS-TTR Rx at the XV International Symposium on Amyloidosis
Ticker: IONS
Occurred on: Jul 07, 2016 -
Akcea Therapeutics Announces Completion of Enrollment in Phase 3 COMPASS Trial of Volanesorsen
Ticker: IONS
Occurred on: May 16, 2016 -
Ionis Pharmaceuticals Provides Update on IONIS-TTRRX Program; CARDIO-TTR placed on clinical hold
Ticker: IONS
Occurred on: Apr 07, 2016 -
Ionis Pharmaceuticals earns 2.15M payment, on track for Phase 3 clinical Nusinersen trials
Tickers: IONS, BIIB
Occurred on: Jan 12, 2016
Strategic Initiatives (IONS)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
